M.D. Ph.D. Craig B. Granowitz - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role: SVP, Chief Medical Officer
Signature: /s/ Craig B. Granowitz, M.D., Ph.D.
Issuer symbol: LXRX
Transactions as of: 28 Feb 2023
Net transactions value: -$27,628
Form type: 4
Filing time: 01 Mar 2023, 15:50:54 UTC
Previous filing: 13 Feb 2023
Next filing: 12 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXRX	Common Stock	Options Exercise		+27,917			27,917	28 Feb 2023	Direct	F1
transaction	LXRX	Common Stock	Tax liability	$27,628	-12,732	-46%	$2.17	15,185	28 Feb 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXRX	Restricted Stock Units	Options Exercise		-27,917	-33%		55,833	28 Feb 2023	Common Stock	27,917		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock.
F2	Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3	Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.